Abstracts tagged "corticosteroids and rheumatoid arthritis (RA)"

Abstract Number: 2485 • 2016 ACR/ARHP Annual Meeting
Correlates of Successful Flare Management: The Role of Clinician-Driven Treatment, Home-Based Strategies, and Medication Change
Taysir G. Mahmoud¹, M Frits², Christine Iannaccone³, Vivian P. Bykerk⁴, Clifton Bingham III⁵, Michael Weinblatt³ and N A Shadick², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Flares are a common experience in RA, often associated with worse clinical outcomes such as cardiovascular disease, lower functional status, and radiographic progression. …
Abstract Number: 2766 • 2015 ACR/ARHP Annual Meeting
Glucocorticoid-Sparing Effects of Abatacept in Real Life Practice: Data from a Paneuropean Analysis of RA Registries
Jacques Gottenberg¹, Xavier Mariette², Maria Victoria Hernandez³, Florenzo Iannone⁴, Elisabeth Lie⁵, Helena Canhão⁶, Karel Pavelka⁷, Carl Turesson⁸, Merete Lund Hetland⁹ and Axel Finckh¹⁰, ¹Hautepierre, Strasbourg, France, ²Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ³Biobadaser, Barcelona, Spain, ⁴Bari University, Rheumatology, Bari, Italy, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, Lisbonne, Portugal, ⁷Charles University, Prague, Czech Republic, ⁸Lund University, Rheumatology, Dept. of Clinical Sciences,, Malmö, Sweden, ⁹DANBIO, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ¹⁰Rheumatology Division, University Hospital of Geneva, Geneva, Switzerland
Background/Purpose: Despite disease modifying anti-rheumatic drugs (bDMARDs), glucocorticoids (GCs) are still widely prescribed in rheumatoid arthritis (RA). GCs are associated with numerous potential side effects,…
Abstract Number: 2375 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Glucocorticoids Sparing Effect: The Spare-1 Study
Alain Saraux¹, Stephanie Rouanet², Rene-Marc Flipo³, Jean-Cyril Poncet⁴, Patrice Fardellone⁵, Pascal Hilliquin⁶, Isabelle Idier⁷ and Alain G. Cantagrel⁸, ¹Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France, ²Medical Department, Roche, Boulogne-Billancourt, France, ³Rheumatology, University Hospital Lille, Lille, France, ⁴Rheumatology, General Hospital Gap, Gap, France, ⁵Service de Rhumatologie, Hôpital Nord, C.H.U. d'Amiens, Amiens, France, ⁶Rheumatology, General Hospital Corbeil, Corbeil-Essonnes, France, ⁷Chugai Pharma, La Defense, France, ⁸Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France
Background/Purpose: Although glucocorticoids (GCs) may be appropriate in rheumatoid arthritis (RA), there is general agreement that GCs sparing is desirable. The safety of GCs is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].